Gastrointestinal stromal tumours

JY Blay, YK Kang, T Nishida… - Nature reviews Disease …, 2021 - nature.com
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Response and resistance to BCR-ABL1-targeted therapies

TP Braun, CA Eide, BJ Druker - Cancer cell, 2020 - cell.com
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

JY Blay, C Serrano, MC Heinrich, J Zalcberg… - The Lancet …, 2020 - thelancet.com
Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …

Kinase-targeted cancer therapies: progress, challenges and future directions

KS Bhullar, NO Lagarón, EM McGowan, I Parmar… - Molecular cancer, 2018 - Springer
The human genome encodes 538 protein kinases that transfer a γ-phosphate group from
ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with …

New treatment strategies for advanced-stage gastrointestinal stromal tumours

LR Klug, HM Khosroyani, JD Kent… - Nature reviews Clinical …, 2022 - nature.com
When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Tumour heterogeneity in the clinic

PL Bedard, AR Hansen, MJ Ratain, LL Siu - Nature, 2013 - nature.com
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines

T Nishida, JY Blay, S Hirota, Y Kitagawa, YK Kang - Gastric cancer, 2016 - Springer
Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …

The quest to overcome resistance to EGFR-targeted therapies in cancer

CR Chong, PA Jänne - Nature medicine, 2013 - nature.com
All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants

BD Smith, MD Kaufman, WP Lu, A Gupta, CB Leary… - Cancer cell, 2019 - cell.com
Summary Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and
PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in …

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …

GD Demetri, P Reichardt, YK Kang, JY Blay… - The Lancet, 2013 - thelancet.com
Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …